The radiopharmaceutical sector has a new player following an agreement between Bristol Myers Squibb Co and RayzeBio Inc to combine forces to give BMS a new portfolio of experimental treatments for cancer focusing on solid tumours. Based in San Diego, US, RayzeBio is a Nasdaq listed company which was founded in 2020 to develop a treatment for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET), or tumours of the gastrointestinal tract. The company’s assets also include potential treatments for small cell lung cancer, hepatocellular carcinoma, and renal cell cancer.
